North America is expected to lead the global recombinant human endostatin market and this is attributed to the high prevalence of cancer in the region which is creating demand for such therapy. According to a report by the Centers for Disease Control and Prevention (CDC), around 1,633,390 new cancer cases were reported in the U.S. in 2015 and the number is expected to reach 1,735,350 in 2018. Also, an increasing number of clinical trials is again expected to foster the growth of the market.
A growing number of research & development activities to recognize potential applications of recombinant human endostatin is expected to foster the growth of the recombinant human endostatin market. Increasing demand for cancer treatment and ongoing studies to identify potential collagen are again fostering the growth of the market. According to the World Health Organization (WHO), around 18.1 million new cases of cancer were recorded in 2018, with 9.6 million deaths due to the disease. Also, the rise in the geriatric population around the globe coupled with the expanding pharmaceutical & biotechnology companies using recombinant human endostatin is further projected to foster the growth of the market. .. Read more